|
1
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Pilotti S, Collini P, Manzari A, Marubini
E and Rilke F: Poorly differentiated forms of papillary thyroid
carcinoma: distinctive entities or morphological patterns? Semin
Diagn Pathol. 12:249–255. 1995.PubMed/NCBI
|
|
4
|
Nishida T, Katayama S, Tsujimoto M,
Nakamura J and Matsuda H: Clinicopathological significance of
poorly differentiated thyroid carcinoma. Am J Surg Pathol.
23:205–211. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aratake Y, Nomura H, Kotani T, et al:
Coexistent anaplastic and differentiated thyroid carcinoma: an
immunohistochemical study. Am J Clin Pathol. 125:399–406. 2006.
View Article : Google Scholar
|
|
6
|
Rosen JM and Jordan CT: The increasing
complexity of the cancer stem cell paradigm. Science.
324:1670–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ke CC, Liu RS, Yang AH, et al:
CD133-expressing thyroid cancer cells are undifferentiated,
radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol
Imaging. 40:61–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng X, Cui D, Xu S, Brabant G and
Derwahl M: Doxorubicin fails to eradicate cancer stem cells derived
from anaplastic thyroid carcinoma cells: characterization of
resistant cells. Int J Oncol. 37:307–315. 2010.PubMed/NCBI
|
|
10
|
Todaro M, Iovino F, Eterno V, et al:
Tumorigenic and metastatic activity of human thyroid cancer stem
cells. Cancer Res. 70:8874–8885. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun JY, Kim YA, Choe JY, et al: Expression
of cancer stem cell markers is more frequent in anaplastic thyroid
carcinoma compared to papillary thyroid carcinoma and is related to
adverse clinical outcome. J Clin Pathol. Aug 28–2013.(Epub ahead of
print). View Article : Google Scholar
|
|
12
|
Takano T: Fetal cell carcinogenesis of the
thyroid: theory and practice. Semin Cancer Biol. 17:233–240. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takano T and Amino N: Fetal cell
carcinogenesis: a new hypothesis for better understanding of
thyroid carcinoma. Thyroid. 15:432–438. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ratajczak MZ: Cancer stem cells - normal
stem cells ‘Jedi’ that went over to the ‘dark side’. Folia
Histochem Cytobiol. 43:175–181. 2005.
|
|
15
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu L, Gibson P, Currle DS, et al:
Prominin 1 marks intestinal stem cells that are susceptible to
neoplastic transformation. Nature. 457:603–607. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barker N, Ridgway RA, van Es JH, et al:
Crypt stem cells as the cells-of-origin of intestinal cancer.
Nature. 457:608–611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaffer CL, Brueckmann I, Scheel C, et al:
Normal and neoplastic nonstem cells can spontaneously convert to a
stem-like state. Proc Natl Acad Sci USA. 108:7950–7955. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albores-Saavedra J, Hernandez M,
Sanchez-Sosa S, Simpson K, Angeles A and Henson DE: Histologic
variants of papillary and follicular carcinomas associated with
anaplastic spindle and giant cell carcinomas of the thyroid: an
analysis of rhabdoid and thyroglobulin inclusions. Am J Surg
Pathol. 31:729–736. 2007. View Article : Google Scholar
|
|
21
|
Lan L, Luo Y, Cui D, et al:
Epithelial-mesenchymal transition induces cancer stem cell
generation in human thyroid cancer cells in vitro. Zhonghua Yi Xue
Za Zhi. 93:1261–1265. 2013.(In Chinese).
|
|
22
|
Yasui K, Shimamura M, Mitsutake N and
Nagayama Y: SNAIL induces epithelial-to-mesenchymal transition and
cancer stem cell-like properties in aldehyde
dehydroghenase-negative thyroid cancer cells. Thyroid. 23:989–996.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clarke MF, Dick JE, Dirks PB, et al:
Cancer stem cells - perspectives on current status and future
directions: AACR Workshop on Cancer Stem Cells. Cancer Res.
66:9339–9344. 2006. View Article : Google Scholar
|
|
26
|
Ailles LE and Weissman IL: Cancer stem
cells in solid tumors. Curr Opin Biotechnol. 18:460–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Golebiewska A, Brons NH, Bjerkvig R and
Niclou SP: Critical appraisal of the side population assay in stem
cell and cancer stem cell research. Cell Stem Cell. 8:136–147.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pastrana E, Silva-Vargas V and Doetsch F:
Eyes wide open: a critical review of sphere-formation as an assay
for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Douville J, Beaulieu R and Balicki D:
ALDH1 as a functional marker of cancer stem and progenitor cells.
Stem Cells Dev. 18:17–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greve B, Kelsch R, Spaniol K, Eich HT and
Gotte M: Flow cytometry in cancer stem cell analysis and
separation. Cytometry A. 81:284–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thomas T, Nowka K, Lan L and Derwahl M:
Expression of endoderm stem cell markers: evidence for the presence
of adult stem cells in human thyroid glands. Thyroid. 16:537–544.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grosse-Gehling P, Fargeas CA, Dittfeld C,
et al: CD133 as a biomarker for putative cancer stem cells in solid
tumours: limitations, problems and challenges. J Pathol.
229:355–378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miraglia S, Godfrey W, Yin AH, et al: A
novel five-transmembrane hematopoietic stem cell antigen:
isolation, characterization, and molecular cloning. Blood.
90:5013–5021. 1997.PubMed/NCBI
|
|
34
|
Zito G, Richiusa P, Bommarito A, et al:
In vitro identification and characterization of
CD133poscancer stem-like cells in anaplastic thyroid
carcinoma cell lines. PLoS One. 3:e35442008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Friedman S, Lu M, Schultz A, Thomas D and
Lin RY: CD133+anaplastic thyroid cancer cells initiate
tumors in immunodeficient mice and are regulated by thyrotropin.
PLoS One. 4:e53952009.
|
|
36
|
Zhu W, Hai T, Ye L and Cote GJ: Medullary
thyroid carcinoma cell lines contain a self-renewing
CD133+population that is dependent on Ret proto-oncogene
activity. J Clin Endocrinol Metab. 95:439–444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin RY: New insights into thyroid stem
cells. Thyroid. 17:1019–1023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goodell MA, Brose K, Paradis G, Conner AS
and Mulligan RC: Isolation and functional properties of murine
hematopoietic stem cells that are replicating in vivo. J Exp Med.
183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robinson SN, Seina SM, Gohr JC, Kuszynski
CA and Sharp JG: Evidence for a qualitative hierarchy within the
Hoechst-33342 ‘side population’ (SP) of murine bone marrow cells.
Bone Marrow Transplant. 35:807–818. 2005.PubMed/NCBI
|
|
40
|
Hoshi N, Kusakabe T, Taylor BJ and Kimura
S: Side population cells in the mouse thyroid exhibit
stem/progenitor cell-like characteristics. Endocrinology.
148:4251–4258. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mitsutake N, Iwao A, Nagai K, et al:
Characterization of side population in thyroid cancer cell lines:
cancer stem-like cells are enriched partly but not exclusively.
Endocrinology. 148:1797–1803. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Steuer B, Breuer B and Alonso A:
Differentiation of EC cells in vitro by the fluorescent dye
Hoechst 33342. Exp Cell Res. 186:149–157. 1990.PubMed/NCBI
|
|
43
|
Adhikari JS, Khaitan D, Arya MB and
Dwarakanath BS: Heterogeneity in the radiosensitizing effects of
the DNA ligand Hoechst-33342 in human tumor cell lines. J Cancer
Res Ther. 1:151–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pillai R, Caria P, Cabras S, Saba F, Vanni
R and Sogos V: Thyrospheres enriched in stem-like cells from B-CPAP
thyroid cancer cell line: morphomolecular characterization. Italian
J Anat Embryol. 116:1432011.
|
|
45
|
Malaguarnera R, Frasca F, Garozzo A, et
al: Insulin receptor isoforms and insulin-like growth factor
receptor in human follicular cell precursors from papillary thyroid
cancer and normal thyroid. J Clin Endocrinol Metab. 96:766–774.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li W, Reeb AN, Sewell WA, Elhomsy G and
Lin RY: Phenotypic characterization of metastatic anaplastic
thyroid cancer stem cells. PLoS One. 8:e650952013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ginestier C, Hur MH, Charafe-Jauffret E,
et al: ALDH1 is a marker of normal and malignant human mammary stem
cells and a predictor of poor clinical outcome. Cell Stem Cell.
1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Han M and Wu C: Advancement of studies on
ALDH1 as a universal marker of stem cells. Sheng Wu Yi Xue Gong
Cheng Xue Za Zhi. 27:1183–1186. 2010.(In Chinese).
|
|
50
|
Feng JQ, Xu ZY, Shi LJ, Wu L, Liu W and
Zhou ZT: Expression of cancer stem cell markers ALDH1 and Bmi1 in
oral erythroplakia and the risk of oral cancer. J Oral Pathol Med.
42:148–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shenoy A, Butterworth E and Huang EH: ALDH
as a marker for enriching tumorigenic human colonic stem cells.
Methods Mol Biol. 916:373–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Klonisch T, Hoang-Vu C and
Hombach-Klonisch S: Thyroid stem cells and cancer. Thyroid.
19:1303–1315. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Carina V, Zito G, Pizzolanti G, et al:
Multiple pluripotent stem cell markers in human anaplastic thyroid
cancer: the putative upstream role of SOX2. Thyroid. 23:829–837.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schweppe RE, Klopper JP, Korch C, et al:
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
cell lines reveals cross-contamination resulting in cell line
redundancy and misidentification. J Clin Endocrinol Metab.
93:4331–4341. 2008. View Article : Google Scholar
|
|
55
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24+liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011.
|
|
56
|
Kim E, Kim M, Woo DH, et al:
Phosphorylation of EZH2 activates STAT3 signaling via STAT3
methylation and promotes tumorigenicity of glioblastoma stem-like
cells. Cancer Cell. 23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tseng LM, Huang PI, Chen YR, et al:
Targeting signal transducer and activator of transcription 3
pathway by cucurbitacin I diminishes self-renewing and
radiochemoresistant abilities in thyroid cancer-derived
CD133+cells. J Pharmacol Exp Ther. 341:410–423. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sarkar A and Hochedlinger K: The sox
family of transcription factors: versatile regulators of stem and
progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen G, Xu S, Renko K and Derwahl M:
Metformin inhibits growth of thyroid carcinoma cells, suppresses
self-renewal of derived cancer stem cells, and potentiates the
effect of chemotherapeutic agents. J Clin Endocrinol Metab.
97:E510–E520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Messina M and Robinson BG: Technology
insight: gene therapy and its potential role in the treatment of
medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab.
3:290–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Naughton CK, Jain S, Strickland AM, Gupta
A and Milbrandt J: Glial cell-line derived neurotrophic
factor-mediated RET signaling regulates spermatogonial stem cell
fate. Biol Reprod. 74:314–321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Short SC, Suovuori A, Cook G, Vivian G and
Harmer C: A phase II study using retinoids as redifferentiation
agents to increase iodine uptake in metastatic thyroid cancer. Clin
Oncol (R Coll Radiol). 16:569–574. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar
|
|
65
|
De Falco V, Tamburrino A, Ventre S, et al:
CD44 proteolysis increases CREB phosphorylation and sustains
proliferation of thyroid cancer cells. Cancer Res. 72:1449–1458.
2012.PubMed/NCBI
|
|
66
|
Liu J and Brown RE: Immunohistochemical
detection of epithelial mesenchymal transition associated with
stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp
Pathol. 3:755–762. 2010.PubMed/NCBI
|
|
67
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
68
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
69
|
Hirschmann-Jax C, Foster A, Wulf G, et al:
A distinct ‘side population’ of cells with high drug efflux
capacity in human tumor cells. Proc Natl Acad Sci USA.
101:14228–14233. 2004.
|
|
70
|
Feng F, Wang H, Fu H, et al:
Dedifferentiation of differentiated thyroid carcinoma cell line
FTC-133 is enhanced by 131I pretreatment. Nucl Med Biol.
38:1053–1058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Robbins RJ and Schlumberger MJ: The
evolving role of 131I for the treatment of
differentiated thyroid carcinoma. J Nucl Med. 46:28S–37S. 2005.
|
|
72
|
Pajonk F, Vlashi E and McBride WH:
Radiation resistance of cancer stem cells: the 4 R’s of
radiobiology revisited. Stem Cells. 28:639–648. 2010.
|
|
73
|
Milas L and Hittelman WN: Cancer stem
cells and tumor response to therapy: current problems and future
prospects. Semin Radiat Oncol. 19:96–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Takakura N: Formation and regulation of
the cancer stem cell niche. Cancer Sci. 103:1177–1181. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nie D: Cancer stem cell and niche. Front
Biosci. 2:184–193. 2010. View
Article : Google Scholar
|
